Skip to content
lifestyle.projectdiaspora.org
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Theolytics
Theolytics to Showcase its Innovative Oncolytic Immunotherapy Strategy – including THEO-260 in Advanced Ovarian Cancer – at Upcoming Investor and Scientific Events
September 16, 2026
Theolytics’ Ongoing US Phase 1 OCTOPOD-IP Trial of THEO-260 in Ovarian Cancer to be Presented as a Trial in Progress at ASCO 2026
May 28, 2026
Theolytics Announces First Patient Dosed in the OCTOPOD-IP Trial, a US Phase 1 Trial with THEO-260, a Novel Oncolytic Immunotherapy Targeting Ovarian Cancer
May 5, 2026